Helicobacter pylori susceptibility testing methods
By Dr. Zubair Khalid, DVM, MS, PhD ·
Quick Answer
- Agar dilution remains the reference method for Helicobacter pylori susceptibility testing, but it is labor-intensive and impractical for routine clinical laboratories.
- Etest provides a practical alternative for individual isolates, though results can vary with inoculum density and media conditions.
- Molecular detection of resistance mutations offers rapid results but only covers known genetic determinants and cannot detect all resistance mechanisms.
At a Glance
| Method | Principle | Best Use Case | Key Limitation |
|---|---|---|---|
| Agar Dilution | Serial twofold dilutions of antibiotic incorporated into agar plates | Reference testing, research, and surveillance studies | Labor-intensive, requires 3 to 5 days for results |
| Etest | Continuous antibiotic gradient on a plastic strip placed on inoculated agar | Single isolate testing in clinical laboratories | Strip cost, potential endpoint reading variability |
| Molecular Methods | PCR-based detection of specific resistance mutations | Rapid detection of clarithromycin resistance from biopsies or cultures | Only detects known mutations, cannot assess phenotypic resistance |
Understanding Helicobacter pylori Susceptibility Testing
Helicobacter pylori is a gram-negative, microaerophilic bacterium that colonizes the human gastric mucosa and is a major cause of chronic gastritis, peptic ulcer disease, and gastric cancer. The organism's fastidious growth requirements make antimicrobial susceptibility testing (AST) more challenging than for many other clinically significant bacteria. Standard AST methods developed for rapidly growing aerobes often fail to support H. pylori growth or produce unreliable results.
The clinical importance of H. pylori susceptibility testing has grown with the rise of antimicrobial resistance. The World Health Organization has identified antimicrobial resistance as a global public health threat, and H. pylori resistance to clarithromycin, metronidazole, and levofloxacin is now common in many regions. Resistance to clarithromycin is particularly problematic because it is a key component of standard eradication regimens. When resistance is present, treatment failure rates increase substantially, leading to repeated courses of therapy and further selection of resistant strains.
The Clinical and Laboratory Standards Institute (CLSI) provides standards for antimicrobial susceptibility testing, including guidance for H. pylori. These standards establish the reference methods, quality control organisms, and interpretive criteria used by clinical laboratories. However, CLSI standards are not universally adopted, and many laboratories use alternative methods or rely on local protocols. The lack of a single standardized method for routine H. pylori AST is a significant challenge for laboratory professionals.
The choice of susceptibility testing method depends on the laboratory's resources, the volume of testing, and the clinical question being addressed. Agar dilution is the reference method and is used for research and surveillance. Etest is a practical alternative for individual isolates. Molecular methods are increasingly used for rapid detection of resistance mutations, particularly for clarithromycin. Each method has its own strengths and limitations, and the laboratory must select the approach that best fits its needs.
Biology and Growth Requirements of Helicobacter pylori
H. pylori is a spiral-shaped, flagellated bacterium that colonizes the mucus layer of the human stomach. It is microaerophilic, requiring an atmosphere with reduced oxygen and increased carbon dioxide. The organism grows slowly, with visible colonies typically appearing after 3 to 5 days of incubation. These growth characteristics are central to the challenges of susceptibility testing.
The organism's natural habitat is the human stomach, and it is not found in environmental reservoirs. The bacterium is transmitted person-to-person, likely through the fecal-oral or oral-oral route. The infection is usually acquired in childhood and persists for decades if untreated. The organism's ability to survive in the acidic gastric environment is due to its urease enzyme, which hydrolyzes urea to produce ammonia and neutralize the local pH.
For laboratory work, H. pylori requires enriched media, such as Columbia agar with horse blood or sheep blood, and a microaerophilic environment. The organism does not grow under standard aerobic or anaerobic conditions. The slow growth rate and specific atmospheric requirements mean that susceptibility testing methods must be adapted to these conditions. Standard AST methods that rely on rapid growth in ambient air are not suitable for H. pylori.
The organism's fastidious nature also affects the interpretation of susceptibility testing results. The inoculum density, the age of the culture, and the type of media can all influence the results. Laboratories must carefully control these variables to obtain reliable data. The use of authenticated reference strains, such as those available from the American Type Culture Collection (ATCC), is essential for quality control and method validation.
Antimicrobial Resistance Mechanisms in H. pylori
Antimicrobial resistance in H. pylori is primarily mediated by point mutations in specific genes, instead of by the acquisition of resistance genes through horizontal transfer. The most clinically important resistance mechanisms are those that affect clarithromycin, metronidazole, and levofloxacin.
Clarithromycin resistance is caused by point mutations in the 23S rRNA gene, which prevent the macrolide from binding to the ribosome. The most common mutations are A2142G and A2143G, although other mutations have been described. These mutations are stable and can be detected by molecular methods. The presence of these mutations is strongly correlated with clinical treatment failure.
Metronidazole resistance is more complex and is associated with mutations in genes involved in the activation of the drug, such as rdxA and frxA. The mechanism is not fully understood, and resistance can be lost or gained during in vitro passage. This instability makes molecular detection of metronidazole resistance difficult and unreliable.
Levofloxacin resistance is caused by mutations in the gyrA gene, which encodes the A subunit of DNA gyrase. The most common mutations are at positions 87 and 91. These mutations can be detected by molecular methods, but the correlation with clinical resistance is less well established than for clarithromycin.
The molecular basis of resistance has important implications for susceptibility testing. Molecular methods can detect known resistance mutations, but they cannot detect resistance that is due to unknown or novel mechanisms. Phenotypic methods, such as agar dilution and Etest, measure the actual susceptibility of the organism and can detect all resistance mechanisms, but they are slower and more labor-intensive.
Agar Dilution Method
Agar dilution is the reference method for H. pylori susceptibility testing. It is the method used to establish the breakpoints and quality control ranges for other methods. The method involves preparing agar plates containing twofold dilutions of the antibiotic, inoculating the plates with a standardized suspension of the organism, and incubating the plates under microaerophilic conditions.
The minimum inhibitory concentration (MIC) is defined as the lowest concentration of the antibiotic that completely inhibits visible growth of the organism. The MIC is read after 3 to 5 days of incubation. The agar dilution method is considered the most accurate and reproducible method for H. pylori susceptibility testing.
The agar dilution method is labor-intensive and time-consuming. It requires the preparation of multiple plates with different antibiotic concentrations, which is a significant amount of work for a single isolate. The method is also not well suited for testing a small number of isolates, as the cost and effort are the same regardless of the number of isolates tested.
The agar dilution method is the method of choice for research studies and for surveillance of antimicrobial resistance. It is also used to validate other methods, such as Etest and molecular methods. The method is not practical for routine clinical testing in most laboratories, but it is essential for establishing the accuracy of other methods.
The quality of the agar dilution method depends on the preparation of the media, the antibiotic concentrations, and the inoculum. The media must be fresh and prepared according to the manufacturer's instructions. The antibiotic concentrations must be accurately prepared and stored. The inoculum must be standardized to ensure that the results are reproducible.
Etest Method
The Etest is a commercial method that uses a plastic strip with a continuous gradient of antibiotic concentrations. The strip is placed on an agar plate that has been inoculated with the test organism. The antibiotic diffuses into the agar, and the MIC is read at the point where the growth of the organism is inhibited.
The Etest is a practical alternative to agar dilution for testing individual isolates. It is easier to perform and requires less time and labor. The Etest is also more flexible, as it can be used to test a single isolate against multiple antibiotics without the need to prepare multiple plates.
The Etest has some limitations. The results can be affected by the inoculum density, the media type, and the incubation conditions. The Etest is also more expensive than agar dilution on a per-isolate basis, as the strips are relatively costly. The Etest is not recommended for testing metronidazole, as the results can be unreliable.
The Etest is a useful method for clinical laboratories that need to test a small number of isolates. It is also a useful method for confirming the results of other methods. The Etest is not a reference method, but it is a practical alternative for routine testing.
The Etest is a method that is widely used in clinical laboratories. It is a simple and reliable method for testing H. pylori susceptibility to clarithromycin and other antibiotics. The Etest is a good choice for laboratories that do not have the resources to perform agar dilution.
Molecular Detection of Resistance Mutations
Molecular methods for H. pylori susceptibility testing detect the presence of known resistance mutations in the bacterial genome. The most common target is the 23S rRNA gene for clarithromycin resistance. Molecular methods can be performed directly on gastric biopsy samples or on cultured isolates.
The main advantage of molecular methods is speed. Results can be obtained in a few hours, compared to several days for culture-based methods. This speed is important for clinical decision-making, as it allows the clinician to select the most appropriate antibiotic regimen for the patient.
The main limitation of molecular methods is that they can only detect known resistance mutations. If the resistance is due to a novel mutation or a different mechanism, the molecular method will not detect it. This limitation is particularly important for metronidazole, where the resistance mechanism is not fully understood.
Molecular methods are also limited by the quality of the sample. The DNA must be of sufficient quality and quantity for the test to be successful. The presence of inhibitors in the sample can also affect the results.
Molecular methods are a valuable tool for H. pylori susceptibility testing, but they are not a replacement for culture-based methods. They are best used in combination with culture-based methods to provide a complete picture of the susceptibility of the organism.
Comparison of Methods
The choice of susceptibility testing method depends on the specific needs of the laboratory and the clinical situation. The agar dilution method is the reference method and is the most reliable, but it is also the most labor-intensive. The Etest is a practical alternative for individual isolates, but it is more expensive and can be less reliable for some antibiotics. Molecular methods are the fastest, but they can only detect known resistance mutations.
The following table summarizes the key differences between the methods:
| Method | Time to Result | Cost per Isolate | Reliability | Detection of Unknown Resistance |
|---|---|---|---|---|
| Agar Dilution | 3 to 5 days | Moderate | High | Yes |
| Etest | 3 to 5 days | High | Moderate | Yes |
| Molecular | Hours | Moderate | High | No |
The agar dilution method is the most reliable, but it is not practical for routine testing. The Etest is a good alternative for clinical laboratories, but it is more expensive. The molecular methods are the fastest, but they are limited to known resistance.
The laboratory should select the method that best fits its needs. The method should be validated and quality controlled to ensure that the results are accurate. The laboratory should also be aware of the limitations of each method and interpret the results accordingly.
Quality Control and Standardization
Quality control is essential for all susceptibility testing methods. The laboratory must use authenticated standard cultures, such as those from the American Type Culture Collection (ATCC), to ensure the accuracy of the results. The quality control organisms should be tested with each batch of media and each new lot of antibiotics.
The quality control organisms should be tested in the same way as the clinical isolates. The results should be within the expected range for the quality control organism. If the results are outside the expected range, the test should be repeated and the problem should be investigated.
The laboratory should also participate in external quality assurance programs to ensure the accuracy of its results. These programs provide a way to compare the laboratory's results with those of other laboratories.
The clinical interpretation of the susceptibility results should be based on the breakpoints established by the CLSI. The breakpoints are the concentrations of the antibiotic that separate susceptible from resistant organisms. The breakpoints are established by the CLSI and are based on the clinical and microbiological data.
The laboratory should report the MIC and the interpretation (susceptible, intermediate, or resistant) for each antibiotic. The report should also include the method used and the quality control results.
Biosafety and Laboratory Practices
H. pylori is a biosafety level 2 (BSL-2) organism. The laboratory should follow the biosafety guidelines for BSL-2 organisms, as described in the Biosafety in Microbiological and Biomedical Laboratories (BMBL) manual. The laboratory should have a biosafety manual and a biosafety officer.
The laboratory should use appropriate personal protective equipment, such as gloves and lab coats. The laboratory should also have a biological safety cabinet for handling the organism. The laboratory should be decontaminated regularly.
The laboratory should also follow the guidelines for the disposal of biological waste. The waste should be decontaminated before disposal.
The laboratory should also be aware of the potential for the organism to be transmitted to laboratory workers. The organism is transmitted through the fecal-oral route, and the laboratory should take precautions to prevent the ingestion of the organism.
Common Failure Patterns and Troubleshooting
The most common failure patterns in H. pylori susceptibility testing are the failure of the organism to grow, the failure of the antibiotic to be active, and the failure of the results to be reproducible.
The failure of the organism to grow is often due to the media or the atmosphere. The media should be fresh and the atmosphere should be microaerophilic. The organism should be incubated for the appropriate time.
The failure of the antibiotic to be active is often due to the preparation of the antibiotic. The antibiotic should be prepared according to the manufacturer's instructions and stored properly.
The failure of the results to be reproducible is often due to the inoculum density. The inoculum should be standardized to ensure that the results are reproducible.
The laboratory should troubleshoot the failure patterns to identify the cause of the problem. The laboratory should also document the failure patterns and the corrective actions.
Professional Escalation Criteria
The laboratory should escalate the results to the clinician when the results are unexpected or when the results are not consistent with the clinical picture. The laboratory should also escalate the results when the organism is resistant to multiple antibiotics.
The laboratory should also escalate the results when the organism is resistant to the antibiotics that are recommended for the treatment of H. pylori. The clinician should be informed of the resistance and the alternative treatment options.
The laboratory should also escalate the results when the organism is resistant to the antibiotics that are recommended for the treatment of H. pylori. The clinician should be informed of the resistance and the alternative treatment options.
Building a Practical H. pylori AST Decision Framework for Your Laboratory
Laboratorians often struggle not with understanding the three main testing approaches, but with deciding which one to use for a given clinical request, workload, and resource level. The existing comparison tables describe what each method does, but they do not provide a step-by-step operational pathway for matching the method to the situation. This section provides a practical decision framework that a laboratory supervisor or clinical microbiologist can implement directly, along with a record system for tracking method performance and troubleshooting guidance that goes beyond simple growth failures.
Step 1: Define the Clinical Question Before Selecting a Method
The first decision point is not about the method at all. It is about what the clinician needs to know and when they need to know it. Clarify the clinical scenario before any testing begins because the answer determines which method is appropriate.
For a patient with a first-time H. pylori infection who has never received macrolide therapy, the pretest probability of clarithromycin resistance is low in most regions. The clinician may not need susceptibility testing at all, and empirical therapy is often appropriate. However, if the patient has failed a previous eradication regimen, the likelihood of resistance increases substantially. In this case, the laboratory should prioritize testing for clarithromycin and levofloxacin resistance, as these are the antibiotics most commonly compromised by prior exposure.
The time to result is a critical factor. If the clinician needs a result within the same day to prescribe therapy, molecular detection of clarithromycin resistance mutations is the only practical option. If the clinician can wait 3 to 5 days, culture-based methods such as agar dilution or Etest are appropriate. The laboratory should establish a policy that defines the turnaround time expectations for each method and communicate this to the clinical team.
The volume of testing is another key variable. A laboratory that receives fewer than five H. pylori isolates per month will find it difficult to maintain proficiency with agar dilution, which requires frequent preparation of antibiotic-containing plates. The Etest is more practical for low-volume testing because strips have a longer shelf life and can be used on an as-needed basis. A laboratory that processes more than 20 isolates per month for surveillance or research purposes should invest in the agar dilution method despite its labor demands.
Step 2: Match the Method to the Laboratory Capability Profile
The decision framework should consider three laboratory capability domains: technical staffing, equipment, and budget. Each method has different requirements in each domain.
Technical staffing is the most important consideration. Agar dilution requires a technologist who can prepare antibiotic stock solutions, calculate dilutions, pour plates, and interpret endpoints after 3 to 5 days of incubation. This is a specialized skill that requires training and ongoing practice. The Etest requires less technical skill for setup, but the endpoint reading requires experience because H. pylori growth can be faint and the inhibition zone edge can be difficult to visualize. Molecular methods require a separate skill set, including DNA extraction, PCR setup, and interpretation of amplification curves or gel bands.
Equipment requirements differ significantly. Agar dilution requires a balance for weighing antibiotic powders, a pH meter for adjusting media, and a plate pourer or manual pouring setup. The Etest requires only standard microbiology equipment, including an incubator with microaerophilic capability. Molecular methods require a thermal cycler, a DNA extraction system, and ideally a real-time PCR instrument for quantitative results. The laboratory must also have separate areas for reagent preparation, sample processing, and amplification to prevent contamination.
The environmental requirements are similar for all culture-based methods. H. pylori requires a microaerophilic atmosphere with reduced oxygen and increased carbon dioxide. This can be achieved with a gas-generating envelope in an anaerobic jar, a CO2 incubator with adjustable gas mixture, or a dedicated microaerophilic workstation. The laboratory must verify that the atmosphere is correct for each run, as failure to maintain the proper gas mixture is a common cause of growth failure.
The decision framework can be summarized as follows. If the laboratory has a low volume of isolates, limited technical staff, and no molecular equipment, the Etest is the most practical choice. If the laboratory has a high volume of isolates, a skilled technical team, and a need for reference-quality data, agar dilution is appropriate. If the laboratory has molecular equipment and the clinical need is for rapid clarithromycin resistance detection, molecular methods are the best fit.
Step 3: Establish a Method Validation Protocol
Before implementing any method for routine use, the laboratory must validate the method against a reference standard. The agar dilution method is the reference method for H. pylori susceptibility testing, and it should be used as the comparator for validation studies. The laboratory should test a panel of isolates that includes susceptible and resistant strains, including authenticated reference strains from the American Type Culture Collection (ATCC) and clinical isolates with known resistance profiles.
The validation protocol should include the following steps. First, select a panel of at least 20 isolates that represent the range of MIC values expected for the antibiotics being tested. Second, test each isolate using the candidate method and the agar dilution reference method in parallel. Third, compare the results to determine the essential agreement, which is the percentage of isolates for which the MIC values are within one twofold dilution of each other. Fourth, determine the categorical agreement, which is the percentage of isolates for which the susceptibility interpretation is the same.
The acceptable performance criteria should be established before the validation begins. A common standard is an essential agreement of at least 90 percent and a categorical agreement of at least 90 percent. If the candidate method does not meet these criteria, the laboratory should investigate the cause and either adjust the method or select a different method.
The validation should also include a reproducibility study. The same isolates should be tested on three separate days to determine the within-laboratory reproducibility. The results should be within one twofold dilution for at least 95 percent of the isolates. This step is important because it identifies whether the method is stable over time and whether the technical staff can perform the method consistently.
Step 4: Establish a Quality Control Schedule
Quality control is not a one-time activity. It must be performed on a regular schedule to ensure that the method continues to produce accurate results. The laboratory should use authenticated reference strains from the ATCC for quality control. These strains have known MIC values for the antibiotics being tested, and the laboratory should verify that the results fall within the expected range.
The quality control schedule should include the following elements. First, test the quality control strains with each new lot of media, each new lot of antibiotic strips or powders, and each new batch of prepared plates. Second, test the quality control strains at least weekly for methods that are used on a regular basis. Third, test the quality control strains whenever there is a change in the equipment, such as a new incubator or a new gas-generating system.
The quality control results should be recorded in a dedicated log. The log should include the date, the method, the antibiotic, the quality control strain, the expected MIC range, and the observed MIC. If the observed MIC is outside the expected range, the laboratory should investigate the cause and document the corrective action. The corrective action may include repeating the test, preparing new media, or contacting the manufacturer of the antibiotic or strip.
The laboratory should also participate in an external quality assurance program. These programs provide unknown isolates for testing and compare the laboratory results with those of other laboratories. Participation in an external program is a valuable way to identify systematic errors that may not be apparent from internal quality control.
Step 5: Use a Decision Matrix for Method Selection
The following decision matrix can be used to select the appropriate method for a given situation. The matrix is based on the clinical question, the laboratory capability, and the volume of testing.
| Clinical Scenario | Laboratory Capability | Recommended Method | Rationale |
|---|---|---|---|
| Treatment failure, result needed within 48 hours | Molecular equipment available | Molecular detection of clarithromycin resistance | Fastest time to result, detects the most common resistance mechanism |
| Treatment failure, result can wait 3 to 5 days | Culture capability | Etest | Practical for individual isolates, no need for plate preparation |
| Surveillance study, high volume of isolates | Full technical capability | Agar dilution | Reference method, most reliable for research data |
| Low volume, no molecular equipment | Basic culture capability | Etest | Cost-effective for occasional testing |
| Research study requiring MIC distribution | Full technical capability | Agar dilution | Provides the most accurate MIC values |
The matrix should be adapted to the specific laboratory. The laboratory should document the decision process and the rationale for each choice. This documentation is useful for training new staff and for defending the laboratory's practices during an audit.
Step 6: Implement a Troubleshooting Log for Method-Specific Failures
The existing article covers general failure patterns, but a practical troubleshooting log should be more specific. The laboratory should maintain a log that records each failure, the suspected cause, the investigation, and the corrective action. The log should be reviewed regularly to identify recurring problems.
For the agar dilution method, the most common failures are related to media preparation. The agar may not solidify properly if the pH is incorrect or if the antibiotic is added at the wrong temperature. The antibiotic stock solution may lose potency if it is not stored properly. The plates may be contaminated if the preparation area is not clean. The troubleshooting log should record the batch number of the media, the antibiotic lot number, and the preparation date for each failure.
For the Etest, the most common failures are related to inoculum density and endpoint reading. If the inoculum is too heavy, the growth may be confluent and the endpoint may be difficult to read. If the inoculum is too light, the growth may be sparse and the endpoint may be falsely low. The laboratory should standardize the inoculum preparation and verify the density with a turbidity standard. The endpoint should be read at the point where the growth is completely inhibited, not where the growth is reduced.
For molecular methods, the most common failures are related to DNA quality and contamination. The DNA extraction may be incomplete, or the sample may contain inhibitors that prevent the PCR reaction. The laboratory should include a positive and negative control in each run to detect these problems. The contamination can occur if the PCR product is handled in the same area as the sample preparation. The laboratory should have a dedicated area for PCR setup and a separate area for PCR amplification.
Step 7: Define Escalation Criteria for Method Selection
The laboratory should have clear criteria for escalating a method selection decision to a supervisor or a medical director. These criteria should be documented and communicated to the staff.
The escalation criteria should include the following situations. First, if the laboratory does not have the capability to perform the method that is clinically indicated, the supervisor should be notified. For example, if a patient has failed treatment and the laboratory does not have molecular capability, the supervisor should decide whether to send the sample to a reference laboratory or to use a culture-based method. Second, if the quality control results are consistently outside the expected range, the supervisor should be notified to investigate the cause. Third, if the laboratory is considering a change in method, the supervisor should be notified to review the validation data and approve the change.
The escalation criteria should also include the situation where the laboratory is considering the use of a method that is not validated. The laboratory should never use a method for clinical testing that has not been validated. If the laboratory does not have the resources to validate a method, it should refer the sample to a reference laboratory.
Step 8: Integrate the Decision Framework into the Laboratory Workflow
The decision framework should be integrated into the laboratory workflow. The laboratory should have a written procedure that describes the steps for selecting a method, performing the test, and reporting the results. The procedure should be reviewed and updated regularly.
The workflow should begin with the receipt of the sample. The laboratory should record the patient information, the clinical question, and the requested antibiotics. The laboratory should then use the decision matrix to select the method. The method should be documented in the laboratory record.
The workflow should include a step for verifying the quality control results before reporting the patient results. If the quality control results are not within the expected range, the patient results should not be reported. The laboratory should investigate the cause and repeat the test if necessary.
The workflow should also include a step for reporting the results to the clinician. The report should include the MIC value, the interpretation, and the method used. The report should also include a comment if the method has limitations that affect the interpretation.
Common Failure Patterns in the Decision Process
The decision process itself can fail in several ways. The most common failure is the selection of a method that does not match the clinical question. For example, a laboratory may use the Etest for a patient who needs a rapid result, and the result is not available in time to guide therapy. The laboratory should review the clinical question before selecting the method.
Another common failure is the selection of a method that does not match the laboratory capability. For example, a laboratory may attempt to perform agar dilution without the necessary equipment or technical skill. The result is often a failed test or an unreliable result. The laboratory should assess its capability before selecting the method.
A third common failure is the lack of a record system. The laboratory may not document the method selection, the quality control results, or the troubleshooting actions. This makes it difficult to identify recurring problems and to demonstrate the accuracy of the results. The laboratory should maintain a complete record for each test.
Professional Escalation Criteria for the Decision Framework
The laboratory should escalate the decision to a supervisor or a clinical director in the following situations. First, if the laboratory cannot provide a result within the required time frame, the supervisor should be notified to coordinate with the clinical team. Second, if the laboratory cannot perform the required method, the supervisor should decide whether to refer the sample to a reference laboratory. Third, if the laboratory has a high rate of quality control failures, the supervisor should investigate the cause and implement corrective action.
The escalation criteria should be documented and communicated to the staff. The staff should know when to escalate and to whom. The escalation should be documented in the laboratory record.
Records and Measurements for the Decision Framework
The laboratory should maintain the following records for the decision framework. First, a log of all susceptibility testing requests, including the clinical question, the method selected, and the rationale for the selection. Second, a log of all quality control results, including the date, the method, the antibiotic, the quality control strain, and the result. Third, a log of all troubleshooting actions, including the failure, the suspected cause, the corrective action, and the outcome.
The laboratory should also maintain a record of the validation study, including the isolates tested, the results, and the agreement calculations. This record is important for demonstrating the accuracy of the method and for the audit.
The records should be reviewed regularly to identify trends. For example, if the laboratory has a high rate of growth failure with the Etest, the review may identify a problem with the media or the atmosphere. The review should lead to corrective action and to the improvement of the method.
The Role of External Standards in the Decision Framework
The decision framework should be aligned with external standards. The Clinical and Laboratory Standards Institute (CLSI) provides standards for antimicrobial susceptibility testing, including the methods and the quality control requirements. The laboratory should follow the CLSI standards for the methods that it uses. The World Health Organization provides guidance on antimicrobial resistance surveillance and stewardship. The laboratory should be aware of the regional resistance patterns and the implications for the testing strategy.
The laboratory should also be aware of the biosafety requirements for handling H. pylori. The Biosafety in Microbiological and Biomedical Laboratories (BMBL) manual provides the guidelines for the biosafety level 2 containment. The laboratory should follow the BMBL guidelines for the handling of the organism and the disposal of the waste.
The decision framework is a practical tool for the laboratory. It provides a step-by-step process for selecting the appropriate method, validating the method, and maintaining the quality of the results. The framework should be adapted to the specific laboratory and should be reviewed and updated regularly.
Frequently Asked Questions
What is the reference method for H. pylori susceptibility testing?
The agar dilution method is the reference method for H. pylori susceptibility testing. It is the method used to establish the breakpoints and quality control values for other methods.
What is the Etest method for H. pylori susceptibility testing?
The Etest is a commercial method that uses a continuous gradient of antibiotic concentration. It is a practical alternative to agar dilution for testing individual isolates.
What are the molecular methods for H. pylori susceptibility testing?
The molecular methods detect the presence of known resistance mutations in the organism. They are the fastest methods, but they can only detect known resistance.
What is the best method for H. pylori susceptibility testing?
The best method depends on the specific needs of the laboratory and the clinical situation. The agar dilution method is the most reliable, but it is the most labor-intensive. The Etest is a good alternative for clinical laboratories. The molecular methods are the fastest, but they are limited to known resistance.
What is the role of quality control in H. pylori susceptibility testing?
Quality control is essential for all susceptibility testing methods. The laboratory must use authenticated standard cultures to ensure the accuracy of the results.
What is the biosafety level for H. pylori?
H. pylori is a biosafety level 2 organism. The laboratory should work with the organism in a biological safety cabinet and follow the biosafety guidelines for BSL-2 organisms.
What is the clinical significance of H. pylori susceptibility testing?
The susceptibility testing is important for the selection of the most effective antibiotic regimen for the patient. The resistance to antibiotics is a major cause of treatment failure.
What is the role of the CLSI in H. pylori susceptibility testing?
The CLSI provides the standards for antimicrobial susceptibility testing, including the methods and the breakpoints for H. pylori. The laboratory should follow the CLSI standards to ensure the accuracy of the results.
Related Bacteriology Guides
- Biological Foundation Models for Antimicrobial Peptide Discovery in Veterinary Pathogens
- Avian Chlamydiosis (Psittacosis) in Pet Birds: Diagnostic Challenges and Molecular Detection
- Trueperella pyogenes: Taxonomy, Virulence, Pathogenesis, Antimicrobial Resistance, and Molecular Epidemiology
- Lyme Disease in Dogs: Borrelia burgdorferi Serological and Molecular Testing in Endemic Regions
- Helicobacter pylori Infection in Cats and Ferrets: Gastric Ulcer Pathogenesis, Diagnosis, and Treatment
References and Further Reading
- Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
- Microbiology Resources. American Society for Microbiology.
- Antimicrobial Resistance. World Health Organization.
- Bacteriological Analytical Manual. U.S. Food and Drug Administration.
- Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute.
- Culture Collections. American Type Culture Collection.
- NCBI Pathogen Detection. National Center for Biotechnology Information.
- Updated joint ESPGHAN/NASPGHAN guidelines for management of Helicobacter pylori infection in children and adolescents (2023).. Journal of pediatric gastroenterology and nutrition, 2024.
- Testing for Helicobacter pylori in an era of antimicrobial resistance.. Journal of clinical microbiology, 2024.
- Culture-Based Antimicrobial Susceptibility Testing for Helicobacter pylori.. Methods in molecular biology (Clifton, N.J.), 2021.
- Overcoming antibiotic-resistant Helicobacter pylori infection: Current challenges and emerging approaches.. World journal of gastroenterology, 2025.
This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.